Redesign Science
and OpenEye Scientific announced that they have entered into a strategic partnership to integrate OpenEye’s Orion computational platform into Redesign’s drug-discovery platform.
Santa Fe, N.M.-based OpenEye makes “cheminformatics” software for drug discovery, providing a reliable application programming interfaces (API) that customers use to build customizable programs and workflows. Its newly released Orion computational platform, built on Amazon Web Services, was designed to extends this capability to be a scalable cloud-based computational analysis system, according to OpenEye. Redesign Science will integrate these tools into its own molecular dynamics platform, allowing it to scale its drug discovery efforts more rapidly.
: “At Redesign, we develop highly customized workflows for each project, and leveraging Orion brings reproducibility, flexibility, and speed to key parts of our development process as we deploy these workflows on the cloud,” said Redesign cofounder and CTO Haotian Li in a news release. “This technology means we can scale up our business without having to scale up human costs and development times at the same rate. It is a major key to Redesign’s growth.”
OpenEye took an equity stake in Mountain View, Calif.-based Redesign during its recently-closed seed investment round.
“OpenEye is committed to advancing rational drug discovery by providing an evolving platform of state-of-the-art methods for pharmaceutical development and analysis,” said OpenEye CEO Anthony Nicholls. “We are excited by Redesign’s vision and how we might help them achieve their goals. We see cloud computing as central to the future of our industry, and investing in Redesign is a part of our broader strategy of engagement with dynamic, revolutionary enterprises.”
Tell Us What You Think!